On April 2, 2026, Profusa, Inc. amended its securities purchase agreement allowing the sale of up to $12.22 million in additional convertible promissory notes and entered a non-binding LOI to acquire assets from Bio Insights LLC for $30 million, projected to enhance revenue through next-gen sequencing in oncology.